- Home
- NUVL vs POST Comparison
NUVL vs POST Comparison
Compare NUVL & POST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- POST
- Stock Information
- Founded
- NUVL 2017
- POST 1895
- Country
- NUVL United States
- POST United States
- Employees
- NUVL N/A
- POST N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- POST Packaged Foods
- Sector
- NUVL Health Care
- POST Consumer Staples
- Exchange
- NUVL Nasdaq
- POST Nasdaq
- Market Cap
- NUVL 5.4B
- POST 6.1B
- IPO Year
- NUVL 2021
- POST N/A
- Fundamental
- Price
- NUVL $80.48
- POST $108.84
- Analyst Decision
- NUVL Strong Buy
- POST Buy
- Analyst Count
- NUVL 10
- POST 6
- Target Price
- NUVL $119.60
- POST $130.50
- AVG Volume (30 Days)
- NUVL 582.7K
- POST 629.7K
- Earning Date
- NUVL 08-07-2025
- POST 07-31-2025
- Dividend Yield
- NUVL N/A
- POST N/A
- EPS Growth
- NUVL N/A
- POST 8.42
- EPS
- NUVL N/A
- POST 5.65
- Revenue
- NUVL N/A
- POST $7,884,600,000.00
- Revenue This Year
- NUVL N/A
- POST $2.63
- Revenue Next Year
- NUVL N/A
- POST $4.32
- P/E Ratio
- NUVL N/A
- POST $19.27
- Revenue Growth
- NUVL N/A
- POST 1.48
- 52 Week Low
- NUVL $55.54
- POST $103.33
- 52 Week High
- NUVL $113.51
- POST $125.84
- Technical
- Relative Strength Index (RSI)
- NUVL 59.85
- POST 44.02
- Support Level
- NUVL $76.27
- POST $107.75
- Resistance Level
- NUVL $80.90
- POST $112.50
- Average True Range (ATR)
- NUVL 2.55
- POST 2.02
- MACD
- NUVL 0.19
- POST -0.14
- Stochastic Oscillator
- NUVL 81.61
- POST 19.26
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About POST Post Holdings Inc.
Post Holdings Inc is an consumer packaged goods holding company. It operates in Post Consumer Brands which Includes branded and private label ready-to-eat cereals, Weetabix Includes the businesses of Weetabix Limited, which Post acquired in July 2017 and which produces and distributes branded and private label RTE cereal, hot cereals and other cereal-based food products, Foodservice which Includes egg and potato products in the foodservice and food ingredient channels from the businesses of MFI Holding Corporation, lastly Refrigerated Retail segment Provides refrigerated retail products, inclusive of side dishes, eggs and egg products, sausage, cheese and other dairy and refrigerated products.